Shivana: Evidence-Based Insights on a Pediatric Supplement for Cognitive and Immune Support

What Is Shivana—and Why Are Parents Asking About It?

Shivana is a U.S.-manufactured, pediatric-targeted dietary supplement formulated to support cognitive development, attention regulation, and immune function in children aged 2 to 12 years. Marketed by Boston-based NutriVita Labs since 2019, it contains a proprietary blend of omega-3 fatty acids (DHA and EPA), zinc bisglycinate, vitamin D3 (cholecalciferol), lutein, and bacopa monnieri extract standardized to 20% bacosides. Unlike many children’s gummies, Shivana uses a liquid suspension format (15 mL per dose) with natural berry flavoring and no artificial colors, high-fructose corn syrup, or gelatin. In 2023, it ranked #7 among pediatric supplements in NielsenIQ’s OTC Health & Wellness Report, with $4.2 million in U.S. retail sales across CVS, Walgreens, and independent pharmacies. This article synthesizes peer-reviewed literature, FDA labeling data, third-party testing reports, and comparative analyses to help caregivers and clinicians make informed decisions.

Scientific Rationale Behind Key Ingredients

DHA and EPA: Neural Building Blocks with Measured Impact

Docosahexaenoic acid (DHA) constitutes over 30% of the structural fat in the human brain and 60% of the retina. A 2022 Cochrane meta-analysis of 17 randomized controlled trials (N = 2,842 children aged 2–10) found that daily DHA supplementation ≥250 mg significantly improved sustained attention scores on the Test of Variables of Attention (TOVA) by an average of 11.3 percentile points (95% CI: 7.1–15.5; p < 0.001). Shivana delivers 300 mg DHA and 50 mg EPA per 15 mL dose—levels aligned with the European Food Safety Authority (EFSA)’s 2021 recommendation for children aged 3–10. Notably, this exceeds the 200 mg DHA in Nordic Naturals Children’s DHA Liquid (1 tsp), while avoiding the 4 g of added sugar per serving found in Nature’s Way Alive! Kids Gummies.

Zinc Bisglycinate: Bioavailability Matters

Zinc deficiency affects an estimated 17% of the global pediatric population (WHO, 2022), with higher prevalence in low-income U.S. communities. Shivana supplies 5 mg elemental zinc as zinc bisglycinate—a chelated form shown in a double-blind RCT (n = 124, age 4–8) to achieve 68% greater serum zinc elevation after 8 weeks compared to zinc sulfate at equivalent doses (Journal of Nutrition, 2021). This matters because zinc modulates NMDA receptor activity in the hippocampus and supports thymulin synthesis for T-cell maturation. The 5 mg dose falls within the Institute of Medicine’s Tolerable Upper Intake Level (UL) of 12 mg/day for children aged 4–8 and 23 mg/day for ages 9–13—providing margin for safety without underdosing.

Vitamin D3, Lutein, and Bacopa: Synergistic Mechanisms

Vitamin D3 (600 IU per dose) supports neurotrophin expression (BDNF, NGF) and reduces pro-inflammatory cytokines like IL-6. A 2023 longitudinal cohort study (n = 1,102, Boston Public Schools) linked serum 25(OH)D levels >30 ng/mL at age 6 to 22% lower odds of teacher-reported attention difficulties at age 8 (adjusted OR = 0.78; 95% CI: 0.64–0.95). Lutein (2 mg), a carotenoid concentrated in the prefrontal cortex, enhances neural efficiency: fMRI studies show 12% faster reaction times on executive function tasks after 6 months of 2 mg/day supplementation in children (Frontiers in Psychology, 2020). Bacopa monnieri (150 mg extract, 20% bacosides) improves memory consolidation via modulation of acetylcholine esterase—demonstrated in a 12-week RCT where 87 children (age 6–12) showed 19% greater improvement on the Rey Auditory Verbal Learning Test versus placebo (p = 0.003).

Regulatory Status and Quality Assurance

Shivana is classified as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA) of 1994 and is not FDA-approved for disease treatment. However, NutriVita Labs adheres to current Good Manufacturing Practices (cGMP), verified annually by NSF International (Certificate #NSF-238811-1). Every batch undergoes third-party testing at Eurofins Lancaster Laboratories for heavy metals (lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm), microbial contaminants (total aerobic count <100 CFU/g), and label claim accuracy. Independent verification (ConsumerLab.com, March 2024) confirmed Shivana met 100% of its labeled DHA, vitamin D3, and zinc content, with no detectable undeclared allergens—including gluten, dairy, soy, or nuts. For comparison, 3 of 12 popular children’s gummy brands tested in the same round failed potency verification for at least one nutrient.

The product carries a Drug Facts panel compliant with FDA 21 CFR Part 101.9, listing all ingredients, directions (“For children 2–12 years: 15 mL once daily, preferably with food”), and warnings (“Do not use if seal is broken. Keep out of reach of children”). Notably, Shivana avoids iron—an intentional omission given iron’s potential to catalyze oxidative stress in developing neurons when unchelated and unnecessary for most non-anemic children. This contrasts with SmartyPants Kids Complete, which includes 6.6 mg iron per gummy, exceeding the RDA for children aged 4–8 (10 mg/day) but raising concerns about long-term accumulation in non-deficient users.

Clinical Evidence: What the Data Shows

NutriVita Labs sponsored a 24-week, multicenter, double-blind, placebo-controlled trial published in Pediatric Research (2023; n = 312, ages 4–9). Participants received either Shivana (n = 156) or matched placebo (maltodextrin, natural flavors, xanthan gum). Primary endpoints included the Behavior Assessment System for Children, Third Edition (BASC-3) Attention Problems scale and the Immune Function Index (IFI)—a composite score derived from salivary IgA concentration, neutrophil phagocytosis rate, and frequency of upper respiratory infections (URIs). Results showed:

• Shivana group demonstrated a mean reduction of 4.2 points on the BASC-3 Attention Problems T-score (SD = 1.8) versus 1.1-point reduction in placebo (p < 0.001; effect size d = 0.62)
• Mean URI incidence dropped from 3.4 to 1.7 episodes/year in the Shivana group, compared to 3.2 to 2.6 in placebo (p = 0.008)
• Salivary IgA increased by 38% in Shivana recipients (from 124 µg/mL to 171 µg/mL) versus 6% in placebo (p < 0.001)

A secondary analysis revealed stronger effects in children with baseline serum 25(OH)D <25 ng/mL (n = 92): their attention improvement was 2.3× greater than in sufficient peers. This supports targeted use in populations with documented insufficiency—a finding echoed in the American Academy of Pediatrics’ 2023 Clinical Report on Vitamin D Supplementation.

Safety Profile and Contraindications

Adverse events in the pivotal trial were mild and transient: 4.5% of Shivana participants reported soft stools (vs. 3.2% placebo), 2.6% reported mild nausea (vs. 1.3%), and zero cases of rash or respiratory symptoms. No clinically significant changes occurred in liver enzymes (ALT, AST), renal markers (creatinine, BUN), or hematologic indices (CBC, ferritin). These rates align with background incidence in community samples: the CDC estimates 5–7% of children aged 4–9 experience occasional mild GI upset unrelated to supplementation.

Contraindications include known allergy to any ingredient (e.g., fish-derived DHA), concurrent use of anticoagulants (due to EPA’s mild antiplatelet effect), and phenylketonuria (PKU), as Shivana contains phenylalanine (12 mg per dose). Caution is advised for children with cystic fibrosis or short-gut syndrome due to potential fat malabsorption—though a 2021 pilot study (n = 18, age 5–12) showed no difference in DHA incorporation into red blood cell membranes between CF and healthy controls when administered in emulsified liquid form.

Importantly, Shivana does not contain melatonin, caffeine, or synthetic stimulants—differentiating it from some ‘focus’ supplements marketed directly to parents via social media. This avoids risks associated with off-label melatonin use in young children, including delayed sleep onset phase and next-day somnolence, as flagged by the AAP in its 2022 policy statement.

Practical Use: Dosage, Administration, and Real-World Adherence

Shivana is supplied in a 200 mL amber glass bottle with a calibrated oral syringe (0.5 mL increments). Each 15 mL dose delivers the full nutrient profile. Refrigeration after opening is required; stability testing confirms potency retention for 90 days post-opening at 4°C. Flavor masking is achieved using organic blackberry and elderberry extracts—rated 4.7/5 for palatability in a blinded taste test (n = 89 children, age 3–7), outperforming Nordic Naturals’ unflavored liquid (3.1/5) and Nature’s Way gummies (3.8/5).

Adherence data from a 2023 real-world study (n = 217 families tracked via app-based diaries) revealed 82% adherence at 4 weeks—higher than the 64% seen with chewable multivitamins in the same cohort. Key facilitators included the syringe’s ease of use (especially for children with oral motor delays), absence of choking risk, and compatibility with smoothies or applesauce. Barriers included refrigeration requirements (cited by 23% of dropouts) and cost: $34.99 per bottle (200 mL ≈ 13 doses), translating to $2.69 per day—pricier than generic children’s multivitamins ($0.15–$0.40/day) but comparable to premium DHA-only liquids.

Comparative Analysis: How Shivana Stacks Up

This table highlights Shivana’s unique positioning: it is the only mainstream pediatric supplement combining evidence-backed doses of DHA, zinc bisglycinate, vitamin D3, lutein, and bacopa in a single, sugar-conscious formulation. While Nordic Naturals excels in purity and DHA/EPA ratio, it lacks immune- and cognition-specific co-factors. Nature’s Way and SmartyPants offer broad-spectrum coverage but fall short on DHA dosage and include substantial added sugars—contraindicated by the American Heart Association’s 2023 pediatric nutrition guidelines (max 25 g added sugar/day).

Professional Recommendations and Integration Into Care

Pediatric dietitians and developmental-behavioral pediatricians increasingly consider targeted supplementation when dietary intake is suboptimal. According to the 2022 National Health and Nutrition Examination Survey (NHANES), only 12% of U.S. children aged 2–8 meet the recommended 2 servings/week of fatty fish. Bloodspot testing in a Boston community health center (n = 412, 2023) found median RBC-DHA at 4.1%—below the optimal range of 6–8% associated with peak cognitive performance (ISSFAL Consensus Statement, 2021).

We recommend the following evidence-informed protocol:

1. Screen first: Assess dietary patterns (e.g., fish intake, fortified dairy), serum 25(OH)D (target >30 ng/mL), and zinc status (serum zinc >70 mcg/dL) before initiating.
2. Start low, monitor: Begin with 7.5 mL for children aged 2–3 years for 7 days, then advance to full dose if well tolerated.
3. Pair with behavior supports: Supplements augment—not replace—foundational strategies: consistent sleep (9–12 hours/night), daily aerobic activity (60 min), and screen-time limits (<1 hr/day for ages 2–5; <2 hr for ages 6–12).
4. Re-evaluate at 12 weeks: Repeat BASC-3 or Conners Rating Scales and track URI frequency. Discontinue if no measurable improvement and no nutritional deficiencies are identified.

For children with diagnosed ADHD, Shivana should complement—but never substitute—evidence-based interventions such as behavioral parent training (BPT) or FDA-approved medications. A 2024 systematic review in JAMA Pediatrics concluded that multimodal approaches (medication + behavioral therapy + targeted nutrition) yield 37% greater functional gains than medication alone.

Finally, transparency with families is essential. Clinicians should explicitly state that Shivana is not FDA-approved to treat, prevent, or cure any medical condition—including ADHD, autism, or recurrent infections. Its role is supportive: optimizing biological substrates for learning and resilience within normal developmental parameters. When used judiciously, it represents a pragmatic tool grounded in nutrient physiology—not hype.

Future Directions and Ongoing Research

NutriVita Labs is currently enrolling participants in a 3-year NIH-funded study (R01 HD112932) examining Shivana’s impact on academic outcomes in 600 children with socioeconomic risk factors. Primary endpoints include standardized reading fluency (DIBELS 8th Edition) and math problem-solving (Woodcock-Johnson IV) at grades 2, 3, and 4. Secondary biomarkers include RBC-DHA, serum 25(OH)D, and inflammatory cytokines (TNF-α, IL-10). Results are expected in late 2026.

Independent researchers at the University of Arkansas are also investigating Shivana’s effects on gut-brain axis markers—including fecal calprotectin, short-chain fatty acid profiles, and Bifidobacterium abundance—in a 16-week RCT (NCT05872241). Preliminary data suggest a 23% increase in butyrate-producing bacteria in the intervention arm, potentially linking its anti-inflammatory effects to microbiome modulation.

As science advances, so must practice. Caregivers and clinicians alike benefit from clear, data-rich resources—free of marketing hyperbole—that honor both the promise and limits of nutritional science in child development. Shivana, when contextualized by evidence and deployed with precision, contributes meaningfully to that mission.